Translating the metastasis paradigm from scientific theory to clinical oncology

Clinical Cancer Research

Volumn 15, Issue 8, 2009, Pages 2588-2593

  Dong, Fei ^a,b   Budhu, Anuradha S ^a   Wang, Xin Wei ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CETUXIMAB; DASATINIB; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; IMATINIB; LAPATINIB; MAPATUMUMAB; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TIPIFAMIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VALATANIB; VANDETANIB;

ANGIOGENESIS; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; HUMAN; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 65249178959     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2356     Document Type: Review

References (44)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8:98-101.
3. Ewing J. Neoplastic diseases. 6th ed. Philadelphia (PA): WB Saunders; 1928.
4. Bross ID, Viadana E, Pickren JW. The metastatic spread of myeloma and leukemias in men. Virchows Arch A Pathol Anat Histol 1975;365:91 -101.
5. Bernards R, Weinberg RA. A progression puzzle. Nature 2002;418:823.
6. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
7. Vona G, Estepa L, Beroud C, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 2004;39: 792-7.
8. Wong IH, Leung T, Ho S, Lau WY, Chan M, Johnson PJ. Semi quantification of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. Br J Cancer 1997;76:628-33.
9. Komeda T, Fukuda Y, Sando T, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer 1995;75: 2214-9.
10. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-5.
11. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532-5.
12. KangY, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
13. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
14. van't Veer LJ, Dai H,Van deVijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
15. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
16. Ye QH, Qin LX, Forgues M,et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-23.
17. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
18. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 2003;100:15901 -5.
19. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-8.
20. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002;38:409-13.
21. Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
22. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-69.
23. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.
24. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71 -8.
25. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev2007;26:373-400.
26. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer- related inflammation. Nature 2008;454:436-44.
27. Vignali DA, Collison LW, Workman CJ. Howregulatory Tcells work. Nat Rev Immunol 2008;8:523-32.
28. Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006;6:141 -6.
29. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-70.
30. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414: 105-11.
31. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2: 442-54.
32. Scheel C, Onder T, Karnoub A, Weinberg RA Adaptation versus selection: the origins of metastatic behavior. Cancer Res 2007;67:11476-9.
33. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347: 1999-2009.
34. Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related micro RNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907.
35. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-67.
36. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OS -774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23: 6657-63.
37. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepato- cellular carcinoma. Cancer 2007;110:581 -9.
38. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 2005;32: S43-47.
39. Llovet JM, Ricci S, Mazzaferro V, et al Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
40. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008;112:250-9.
41. Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep 2008;10:199-205.
42. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell marker EpCAM by Wnt-h-catenin signaling in hepatocellular carcinoma. Cancer Res 2007;67:10831 -9.
43. Yamashita T, Forgues M, Wang W, et al. EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451 -61.
44. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor initiating cells with stem/progenitor cell features. Gastroenterology 2009;136:1012-24.